13F Holdings
中文EN

VRAX Virax Biolabs Group Ltd IFRS Annual reports only

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1885827 · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-96.0%
TTM net income YoY10.0%
TTM EPS YoY51.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-838.2%
Operating margin-97,344.8%
Net margin-95,739.2%
FCF margin-81,621.6%
EBITDA margin-93,133.7%

Returns

ROE-109.6%
ROA-101.8%
ROIC (approx.)-300.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets15.0%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-25.1%
Payout ratio—
Capex / revenue9,538.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31FY20212021-03-31
Income statement
Revenue$6,331$156,419$8,561$0$123,820
Cost of revenue$59,398$105,829$9,926—$133,254
Gross profit-$53,067$50,590-$1,365—-$9,434
R&D expense$1.78M$1.56M$2.18M$433,743$120,221
SG&A expense$4.33M$4.59M$3.55M$1.30M$457,680
Operating income-$6.16M-$6.50M-$5.73M-$1.73M-$644,538
Pretax income-$6.20M-$6.74M-$5.46M-$1.75M-$672,915
Income tax-$136,661————
Net income-$6.06M-$6.73M-$5.46M-$1.71M-$650,984
EBITDA-$5.90M-$6.44M———
EPS (basic)-1.62-3.36-5.13-1.79—
EPS (diluted)-1.62-3.36-5.13-1.79—
Weighted avg. shares (diluted)3.73M2.01M1.06M956,3261.58M
Banking
Net interest income$58,179-$26,878-$15,468-$15,438-$28,643
Balance sheet
Cash & equivalents$4.23M$3.59M$9.35M$21,756$17,621
Receivables————$928
Inventory$94,675$60,383$0$20,951$21,072
Current assets$4.89M$4.38M$9.63M$48,706$39,621
PP&E, netmay include right-of-use assets (IFRS)$1.23M$897,627———
Intangibles——$178,403——
Total assets$6.43M$5.48M$9.81M$48,706$39,621
Current liabilities$673,207$168,849$908,401$1.25M$871,435
Total liabilities$964,750$345,194$908,401$1.25M$871,435
Shareholders' equity$5.70M$5.37M$9.13M-$974,578-$650,682
Shares outstanding4.34M2.57M1.55M9.98M—
Cash flow statement
Operating cash flow-$4.56M-$6.25M-$4.18M-$809,070-$590,186
Capital expenditure$603,890$952,497———
Free cash flow-$5.17M-$7.20M———
Investing cash flow-$603,890-$1.16M-$178,403——
Financing cash flow$5.81M$1.65M$13.69M$813,205$585,198
Depreciation & amortization$266,601$54,870———
Stock-based compensation$365,309$1.01M$1.73M$290,364—

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.